Quick Take
ADC Therapeutics (ADCT) intends to raise $125 million from the sale of its common stock, per an amended registration statement.
The company is advancing a pipeline of drug candidates for the treatment of blood cancers and solid tumors.
ADCT is making a new attempt to go public at a reasonable valuation and with strong existing investor interest in supporting the IPO.
Company & Technology
Epalinges, Switzerland-based ADC was founded as a spin-off of Spirogen to develop antibody drug conjugates (ADCs - hence the company's name) for the treatment of hematological